UNSPSC 51142535: Phenglutarimide

This classification denotes an anticholinergic agent with the molecular formula C17H24N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 679RC9H8TG, chemically known as 2,6-piperidinedione, 3-(2-(diethylamino)ethyl)-3-phenyl- but generally known as phenglutarimide, which bears US NIH Compound Identifier 92870. European Medicines Agency schedules Phenglutarimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09762MIG. The term PHENGLUTARIMIDE is an International Non-Proprietary Name.

UNSPSC 51142535 Phenglutarimide is a Commodity code that represents pharmaceutical and chemical compounds used in medical and public-health applications. However, the recent state and local solicitation activity tagged to this code does not reflect procurement of phenglutarimide itself. Instead, Seminole County, Florida posted an IFB for naloxone (an opioid-reversal medication) and safe drug deactivation systems — products that fall outside the nominal scope of this code. The mismatch suggests either a misclassification in the county's tagging or a data error in the source. State and local procurement under the phenglutarimide code itself shows no recent activity beyond this single, off-scope opportunity.

Seminole County is the only recent issuing body visible in the available data. The single IFB (60459723LAS), posted June 30, 2026, with a response deadline of July 26, 2023, calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract includes a two-year initial term with a one-year renewal option and requires vendors to submit electronic bids through the county's e-Procurement Portal, comply with drug-free workplace and E-Verify requirements, and maintain workers' compensation, commercial general liability, and professional liability coverage. No explicit set-aside or disadvantaged-enterprise restrictions are mentioned. Because the solicitation does not align with the code's nominal scope and no other recent opportunities appear in the record, this code shows little decision-relevant state and local procurement activity for firms pursuing phenglutarimide supply.